{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:02:28Z","timestamp":1777723348402,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346381), which evaluated the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients with advanced solid tumors. We herein report the findings from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible patients were enrolled and treated with camrelizumab (200\u00a0mg once every 3\u00a0weeks via intravenous infusion) and oral famitinib (20\u00a0mg once daily). The primary endpoint was the objective response rate (ORR). Secondary endpoints included the disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty patients were enrolled in this cohort, with a median follow-up duration of 11.5\u00a0months. Three patients (7.5%) achieved a partial response, and 29 patients (72.5%) achieved stable disease. The ORR and DCR with this combination regimen were 7.5% (95% CI, 1.6\u201320.4) and 80.0% (95% CI, 64.4\u201390.9), respectively. The median DoR was 12.1\u00a0months (95% CI, 10.3-not reached). The median PFS was 5.4\u00a0months (95% CI, 4.1\u20137.5), and the median OS was 12.1\u00a0months (95% CI, 9.1\u201316.7). The estimated 12-month OS rate was 51.5% (95% CI, 34.9\u201365.9). The most frequent grade 3 or higher treatment-related adverse events occurring in more than 5% of patients included hypertension (27.5%), palmar-plantar erythrodysesthesia syndrome (10%), decreased neutrophil count (10%), and proteinuria (7.5%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Camrelizumab plus famitinib demonstrated favorable benefits in PFS and OS, along with manageable safety profiles, in patients with advanced NSCLC who progressed after platinum-doublet chemotherapy and immunotherapy. This finding warrants further exploration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-024-03715-4","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:01:43Z","timestamp":1715335303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study"],"prefix":"10.1007","volume":"73","author":[{"given":"Shengxiang","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanyong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shegan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"5","key":"3715_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2022) Non-small cell lung cancer, version 3. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 20(5):497\u2013530","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9944","key":"3715_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665\u2013673","journal-title":"Lancet"},{"issue":"2","key":"3715_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143\u2013155","journal-title":"Lancet Oncol"},{"issue":"2","key":"3715_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"17","key":"3715_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"5","key":"3715_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"YL Wu","year":"2019","unstructured":"Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T et al (2019) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 14(5):867\u2013875","journal-title":"J Thorac Oncol"},{"issue":"10027","key":"3715_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550","journal-title":"Lancet"},{"issue":"4","key":"3715_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A et al (2020) Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71(4):1247\u20131261","journal-title":"Hepatology"},{"issue":"15","key":"3715_CR9","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70(15):6171\u20136180","journal-title":"Cancer Res"},{"issue":"4","key":"3715_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C et al (2019) Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res 7(4):630\u2013643","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"3715_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B et al (2022) Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol 40(21):2295\u20132306","journal-title":"J Clin Oncol"},{"issue":"26","key":"3715_CR12","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.19.02627","volume":"38","author":"V Makker","year":"2020","unstructured":"Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL et al (2020) Lenvatinib plus pembrolizumab in patients With advanced endometrial cancer. J Clin Oncol 38(26):2981\u20132992","journal-title":"J Clin Oncol"},{"issue":"16_Supplement","key":"3715_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/1538-7445.AM2020-CT289","volume":"80","author":"NB Leighl","year":"2020","unstructured":"Leighl NB, Hui R, Rodr\u00edguez-Abreu D, Nishio M, Hellmann MD, Lee C et al (2020) Abstract CT289: pembrolizumab plus lenvatinib vs. docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: phase 3, randomized, open-label LEAP-008 trial. Can Res 80(16_Supplement):289","journal-title":"Can Res"},{"issue":"3","key":"3715_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J et al (2021) Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med 9(3):305\u2013314","journal-title":"Lancet Respir Med"},{"issue":"4","key":"3715_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G et al (2022) Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol 17(4):544\u2013557","journal-title":"J Thorac Oncol"},{"issue":"8_Supplement","key":"3715_CR16","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1538-7445.AM2011-3604","volume":"71","author":"L Lou","year":"2011","unstructured":"Lou L, Mi Y, Xu Y, Xie C, Zhao H (2011) Abstract 3604: preclinical antitumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR\/PDGFR\/c-Kit in phase I clinical trials. Can Res 71(8_Supplement):3604\u20133604","journal-title":"Can Res"},{"issue":"1","key":"3715_CR17","doi-asserted-by":"publisher","first-page":"e003831","DOI":"10.1136\/jitc-2021-003831","volume":"10","author":"L Xia","year":"2022","unstructured":"Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W et al (2022) Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer 10(1):e003831","journal-title":"J Immunother Cancer"},{"issue":"21","key":"3715_CR18","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1158\/1078-0432.CCR-21-1698","volume":"27","author":"YY Qu","year":"2021","unstructured":"Qu YY, Zhang HL, Guo H, Luo H, Zou Q, Xing N et al (2021) Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase II basket study. Clin Cancer Res 27(21):5838\u20135846","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3715_CR19","doi-asserted-by":"publisher","first-page":"e004427","DOI":"10.1136\/jitc-2021-004427","volume":"10","author":"Y-Y Qu","year":"2022","unstructured":"Qu Y-Y, Sun Z, Han W, Zou Q, Xing N, Luo H et al (2022) Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. J Immunother Cancer 10(5):e004427","journal-title":"J Immunother Cancer"},{"issue":"22","key":"3715_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093\u20132104","journal-title":"N Engl J Med"},{"issue":"12","key":"3715_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF et al (2019) First-line nivolumab Plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 37(12):992\u20131000","journal-title":"J Clin Oncol"},{"issue":"16","key":"3715_CR22","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.3123","volume":"27","author":"T Koyama","year":"2008","unstructured":"Koyama T, Chen H (2008) Proper inference from Simon\u2019s two-stage designs. Stat Med 27(16):3145\u20133154","journal-title":"Stat Med"},{"issue":"10183","key":"3715_CR23","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819\u20131830","journal-title":"Lancet"},{"issue":"19","key":"3715_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"5","key":"3715_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20(5):711\u2013718","journal-title":"Lancet Oncol"},{"issue":"1","key":"3715_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40880-017-0263-y","volume":"36","author":"RH Xu","year":"2017","unstructured":"Xu RH, Shen L, Wang KM, Wu G, Shi CM, Ding KF et al (2017) Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer 36(1):97","journal-title":"Chin J Cancer"},{"issue":"5","key":"3715_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","volume":"72","author":"A Zhou","year":"2013","unstructured":"Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q et al (2013) Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 72(5):1043\u20131053","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"3715_CR28","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3760\/cma.j.issn.0366-6999.20131757","volume":"126","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zhou AP, Qin Q, Chang CX, Jiang HY, Ma JH et al (2013) Famitinib in metastatic renal cell carcinoma: a single center study. Chin Med J (Engl) 126(22):4277\u20134281","journal-title":"Chin Med J (Engl)"},{"issue":"9863","key":"3715_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"issue":"6","key":"3715_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TC, Ma B, Pan H et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629","journal-title":"Lancet Oncol"},{"issue":"1","key":"3715_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.20892\/j.issn.2095-3941.2018.0172","volume":"16","author":"X Chen","year":"2019","unstructured":"Chen X, Ma L, Wang X, Mo H, Wu D, Lan B et al (2019) Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med 16(1):173\u2013181","journal-title":"Cancer Biol Med"},{"issue":"5","key":"3715_CR32","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","volume":"27","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu K et al (2021) Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin Cancer Res 27(5):1296\u20131304","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3715_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R et al (2019) Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 25(2):515\u2013523","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3715_CR34","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","volume":"27","author":"Z Peng","year":"2021","unstructured":"Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K et al (2021) Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 27(11):3069\u20133078","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03715-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03715-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:51:21Z","timestamp":1718682681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03715-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03715-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HD, SW, and XY report being employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. All remaining authors have declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by institutional review boards or ethic committees at each center, and the study was conducted in accordance with the protocol, Good Clinical Practice guidelines and Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients were required to provide written informed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"124"}}